NCT06190821

Brief Summary

Percutaneous treatment of liver lesions adjacent to the duodenum exposes the duodenum to the risk of thermal injury, limiting removal and oncologic outcome. In this study the investigators investigate the feasibility of hepato duodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 20, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2022

Completed
1.3 years until next milestone

First Posted

Study publicly available on registry

January 5, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
19 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2025

Completed
Last Updated

January 5, 2024

Status Verified

December 1, 2023

Enrollment Period

2.5 years

First QC Date

September 6, 2022

Last Update Submit

December 19, 2023

Conditions

Hepatic Lesions

Keywords

hepatic lesionsliver lesionsduodenumhepato duodenal ligament

Outcome Measures

Primary Outcomes (1)

  • Retrospective description of the hepatoduodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum

    This study is retrospective

    Files analysed retrospectively from January 01, 2019 to July 31, 2022 will be examined

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Major subject (≥18 years of age) who underwent percutaneous ablation of primary or secondary liver lesions at HUS that required per-procedure hepatoduodenal ligament hydrodissection in the interventional imaging department of the New Civil Hospital from January 2019 to July 2022.

You may qualify if:

  • Major subject (≥18 years of age)
  • Subject who underwent percutaneous ablation of primary or secondary liver lesions at HUS that required per-procedure hepatoduodenal ligament hydrodissection in the interventional imaging department of the New Civil Hospital from January 2019 to July 2022.
  • Subject who has not expressed opposition to the reuse of their data for the purpose of this research.

You may not qualify if:

  • \- Opposition to the reuse of his/her data for the purpose of scientific research.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service Imagerie interventionnelle oncologique et viscérale - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

Central Study Contacts

Julien GARNON, MD

CONTACT

33 3.69.55.03.04julien.garnon@chru-strasbourg.fr

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 6, 2022

First Posted

January 5, 2024

Study Start

July 20, 2022

Primary Completion

February 1, 2025

Study Completion

February 20, 2025

Last Updated

January 5, 2024

Record last verified: 2023-12

Locations

FR(1)